Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of SAGE-217 in the Treatment of Adult Subjects With Major Depressive Disorder

NCT04442490 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT04442490
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04442490 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of SAGE-217 in the Treatment of Adult Subjects With Major Depressive Disorder
Lead sponsor
Biogen
Phase
Phase 3
Overall status
Completed
Start date
May 12, 2020
Completion date
April 21, 2021
Enrollment
543 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder, major